# OnCo record impower150 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/impower150/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "impower150", "NCT02366143" ;
  schema:name "IMpower150"@en ;
  schema:description "Added an anti-VEGF antibody to chemotherapy and immunotherapy, and is the one first-line regimen with evidence in people whose cancer is driven by an EGFR or ALK change."@en ;
  schema:url <https://onco.cc/trials/impower150/> ;
  schema:dateModified "2026-09-25"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT02366143>, <https://doi.org/10.1056/NEJMoa1716948>, <https://www.nice.org.uk/guidance/ta584> ;
  onco:status "positive" ;
  onco:phase "3" ;
  onco:cancers <https://onco.cc/cancers/lung-adenocarcinoma/>, <https://onco.cc/cancers/nsclc/>, <https://onco.cc/cancers/egfr-mutant-nsclc/> ;
  onco:technologies <https://onco.cc/technologies/checkpoint-inhibitor/>, <https://onco.cc/technologies/antiangiogenic/>, <https://onco.cc/technologies/cytotoxic-chemotherapy/>, <https://onco.cc/technologies/platinum/> ;
  onco:targets <https://onco.cc/targets/pdl1/>, <https://onco.cc/targets/vegf/> ;
  onco:drugs <https://onco.cc/drugs/atezolizumab/>, <https://onco.cc/drugs/bevacizumab/>, <https://onco.cc/drugs/carboplatin/>, <https://onco.cc/drugs/paclitaxel/> ;
  onco:companies <https://onco.cc/companies/roche-genentech/> ;
  onco:terms <https://onco.cc/terms/immune-checkpoint/>, <https://onco.cc/terms/resistance/> ;
  onco:trials <https://onco.cc/trials/keynote-024-189/> .